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ABSTRACT
Objective To identify observational studies which used 
data from more than one primary care electronic health 
record (EHR) database, and summarise key characteristics 
including: objective and rationale for using multiple data 
sources; methods used to manage, analyse and (where 
applicable) combine data; and approaches used to assess 
and report heterogeneity between data sources.
Design A systematic review of published studies.
Data sources Pubmed and Embase databases were 
searched using list of named primary care EHR databases; 
supplementary hand searches of reference list of studies 
were retained after initial screening.
Study selection Observational studies published 
between January 2000 and May 2018 were selected, 
which included at least two different primary care EHR 
databases.
Results 6054 studies were identified from database 
and hand searches, and 109 were included in the final 
review, the majority published between 2014 and 2018. 
Included studies used 38 different primary care EHR data 
sources. Forty- seven studies (44%) were descriptive 
or methodological. Of 62 analytical studies, 22 (36%) 
presented separate results from each database, with no 
attempt to combine them; 29 (48%) combined individual 
patient data in a one- stage meta- analysis and 21 (34%) 
combined estimates from each database using two- stage 
meta- analysis. Discussion and exploration of heterogeneity 
was inconsistent across studies.
Conclusions Comparing patterns and trends in different 
populations, or in different primary care EHR databases 
from the same populations, is important and a common 
objective for multi- database studies. When combining 
results from several databases using meta- analysis, 
provision of separate results from each database is helpful 
for interpretation. We found that these were often missing, 
particularly for studies using one- stage approaches, which 
also often lacked details of any statistical adjustment 
for heterogeneity and/or clustering. For two- stage meta- 
analysis, a clear rationale should be provided for choice of 
fixed effect and/or random effects or other models.
INTRODUCTION
Multi- database observational studies are 
increasingly common. They are conducted 
for two main reasons: to compare results 
across diverse populations and healthcare 
settings, or to combine the data to increase 
statistical power. Primary care electronic 
health record (EHR) databases are particu-
larly valuable because they provide longitu-
dinal data on individuals, often over many 
years, and typically contain richer informa-
tion on a broader range of exposures, risk 
factors and health outcomes than administra-
tive databases.1–3 Although individual primary 
care EHR databases are often relatively small, 
covering a single region or other national 
population subset, their growing availability 
in recent years is likely to further increase 
the importance of non- interventional studies, 
which combine these databases. Guidelines 
identifying best practice in this context have 
yet to be established but would be of clear 
benefit for researchers working with multiple 
databases. An important preliminary step is 
to describe current practice, but there is no 
comprehensive summary of studies which 
Strengths and limitations of this study
 ► Our systematic review identified the increasing 
number of published observational studies, which 
specifically used primary care electronic health re-
cord (EHR) data from two or more sources.
 ► There were no restrictions on study design, expo-
sures or outcomes.
 ► In the absence of relevant Medical Subject Heading 
terms, the search strategy relied on an extensive list 
of named primary care EHR databases to achieve as 
comprehensive coverage as possible.
 ► The selected publications were independently re-
viewed by two researchers.
 ► The findings of this review may not apply to multi- 
database studies, which did not use primary care 
EHR data sources.
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used two or more primary care EHR databases, and the 
methods for combining them.
One previous systematic review focused on multi- 
database pharmacoepidemiology studies with a 
pre- planned approach to combine data to evaluate drug- 
outcome associations.4 In that review, studies were not 
limited according to the types of databases used, but 
descriptive studies and those which did not combine 
results from different databases were excluded. The 
authors found that for data management arrangements, 
analysis of heterogeneity and methods for combining 
data reporting were often inadequate, making interpre-
tation of study results more challenging. Since the focus 
of that review was pharmacoepidemiology studies and a 
wide range of database types, a broader view of combined 
primary care EHR data for any study purpose remains 
lacking.
The aim of this systematic review was to identify and 
describe the full range of completed studies which 
brought together primary care EHR data from two or 
more sources. The specific objectives were to summarise 
key study characteristics, including the main reasons or 
motivations for including data from different EHR data-
bases; to describe the methods used to manage, analyse 
and (where applicable) combine data; and describe 
the approaches used to assess and report heterogeneity 
between primary care EHR data sources.
METHODS
The review considered all multi- database studies, 
published in English language between 2000 and 2018, 
and which included at least two different primary care 
EHR databases or data sources, irrespective of whether 
other types of database were also included. Primary care 
EHR data was defined as data collected by primary care 
clinicians and related staff for the purpose of diagnosis, 
treatment, management and delivery of care of indi-
vidual patients, and could include information contrib-
uted by other care providers.5 It excluded data generated 
primarily for administrative purposes such as health insur-
ance claims data, where the motivation for recording is 
different. Primary care EHR databases were considered 
irrespective of whether they were ‘vertically’ linked (ie, 
linked at the individual patient level) to another data 
source such as a disease registry or dispensing database. 
Each ‘vertically’ linked primary care EHR database was 
treated as a single data source. Apart from the specific 
focus on primary care EHR databases, no other restric-
tions were applied in terms of populations, geography, 
study period, exposure, outcome or study design.
A previous systematic review highlighted the chal-
lenge of identifying multi- database studies, for which 
no specific Medical Subject Heading (MeSH) terms 
exist.4 An alternative approach was, therefore, used, 
based on a comprehensive list of named primary 
care EHR databases compiled from two online regis-
ters6 7 and one systematic review of primary care data 
collection projects.8 For each named database, a 
keyword search was generated and run on Medline, 
and the results combined. Abstracts of published 
studies identified in this search were scanned for 
additional terms and phrases, which might be used to 
describe the primary care EHR data sources, and from 
these additional keyword searches were generated. 
The final search strategy (see online supplemental 
material) was used to identify studies in Medline and 
Embase databases published between January 2000 
and May 2018.
Titles and abstracts of all retrieved studies were 
screened for eligibility by one reviewer (DD). A random 
20% sample was also screened by a second reviewer (MC) 
and showed very good agreement between the two. Refer-
ence lists of papers selected for full review were hand 
searched for additional studies.
Full text was obtained for all papers selected during 
the initial screening, and read by two reviewers (DD and 
MC), who independently completed the final eligibility 
assessment and data extraction. Each reviewer extracted 
standardised information from the study publication and 
online supplemental materials (where available), which 
was entered into the review database (Microsoft Access) 
via electronic data collection form developed by one of 
the reviewers (DD), and pilot tested with seven studies. 
Information extracted included data sources used, main 
objectives, study design, study populations, exposure, 
comparators and outcomes, data management arrange-
ments and statistical methods. All discordant results 
were reviewed, and the final designation agreed by both 
reviewers. No additional information was sought from 
investigators.
Studies were classified as analytical if they esti-
mated an exposure–outcome association, or 
descriptive otherwise. We noted whether and how 
between- database heterogeneity was assessed, how 
this informed the decision to combine the data and 
whether a one- stage meta- analysis of pooled individual 
patient data (IPD) or two- stage meta- analysis of study- 
specific effect estimates was used, as well as choice of 
fixed- effects (FE) versus random- effects (RE) models. 
A clear rationale for using multiple data sources was 
not always stated, but in some instances could be 
inferred. For analytical studies where results were 
combined using one- stage or two- stage meta- analysis, 
unless stated otherwise the rationale was assumed to 
be an increase in the statistical precision of the expo-
sure–outcome effect estimate. Three main models for 
data management and analysis were considered, based 
on previous reviews4 9–11: a fully centralised model for 
management and analysis of the raw data provided by 
each contributing database; a fully distributed model 
where all data management and analysis was under-
taken locally, and only fully aggregated results were 
shared; and a partially distributed model with local 
extraction and data management to generate stan-
dardised patient level or partially aggregated datasets 
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in standardised format, which were then shared for 
final centralised analysis. Partially aggregated (or 
semi- aggregated) data summarise information on 
more than one individual (thereby enhancing privacy 
protection) while still allowing the pooling of data 
across databases for further analysis, including one- 
stage meta- analysis. Examples include total person 
time and event counts for groups of patients sharing 
the same characteristics.
We noted whether studies used a global common data 
model (CDM) such as those from OMOP (Observational 
Medical Outcomes Partnership)12 13 or Sentinel,14 15 and 
whether they were part of a wider programme or initia-
tive for developing database networks and methods for 
combining results—such as IMI- PROTECT (Innovative 
Medicines Initiative Pharmacoepidemiological Research 
on Outcomes of Therapeutics by a European Consor-
Tium),16 17 EU- ADR(European Union Adverse Drug 
Reaction database network)18 or ARITMO (Arrhythmo-
genic Potential of Medicines project).19 20
The focus of the review was on describing the range 
of multi- database studies and methods for combining 
primary care EHR data, rather than evaluating 
evidence of effectiveness of specific interventions. 
Given this, and in the absence of consensus or vali-
dated reporting guidelines for multi- database studies, 
no formal assessment of risk of bias or study quality 
was attempted.
The study protocol, including the final Medline search 
strategy and details of data items extracted, is provided in 
online supplemental file 1.
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research.
RESULTS
The Medline and Embase searches returned 6049 results, 
and a further 5 were identified by hand searches. After 
initial screening of abstracts, 138 papers were selected for 
full text review, and 109 were included in the final review 
(figure 1). Summary information on the included studies 
is provided in online supplemental table S1.
Included studies used data from 38 different primary 
care EHR databases. Most studies (98, 89%) used 2 or 3 
primary care EHR databases, and 43 studies (39%) also 
included 1 or more non- primary care EHR database. All 
but 3 studies used exclusively European primary care data, 
and 35 (32%) used data from a single country. Details of 
the primary care EHR databases used in included studies 
are summarised in online supplemental table S2.
The annual number of published studies increased 
over time (online supplemental figure S1), with fewer 
than 10 studies per year between 2003 and 2013, while a 
peak in 2016 (25 studies) included 10 studies published 
in a special supplement on the IMI- PROTECT research 
programme.16 17
General characteristics of included studies are given in 
table 1. More than half (62 studies, 57%) were classified 
as analytical. Most studies (76, 70%) examined safety, 
effectiveness or utilisation of specific drugs accounted for, 
while 21% (23 studies) were disease epidemiology or risk 
prediction studies with no specific focus on pharmacolog-
ical therapies.
Cohort studies were the most common study design (72 
studies, 66%), and the majority of these were descriptive. 
Six studies included more than one study design.
The most common approach for data management 
and analysis was a fully centralised model (44 studies, 
40%). A fully distributed model was used in 23 studies 
(21%), including 15 studies conducted as part of the 
IMI- PROTECT programme.16 21 A partially distributed 
approach was used in 20 studies (18%), including 9 
studies from the EU- ADR programme18 and 5 from the 
ARITMO project.19 20 No studies reported using a CDM.
Methodological aspects of the 62 analytical studies 
are summarised in table 2. All 23 case–control studies 
employed individual matching, and used conditional 
logistic regression to estimate adjusted ORs, but for 
cohort studies a range of statistical approaches was used.
In 22 analytical studies (35%), data were not combined, 
and all results were presented separately for each data-
base—usually in order to describe and assess the consis-
tency of findings in different populations or settings, 
using a common study protocol and analysis approach. 
In the remaining five studies, risk prediction models were 
developed in one primary care EHR database, and vali-
dated using a second primary care EHR database from 
the same country (the UK).22–26
In 40 analytical studies (65%), including the majority 
(20/23) of case–control studies, and half (18/34) of cohort 
studies, some form of pooled analysis or meta- analysis was 
undertaken. A one- stage meta- analysis of pooled IPD or 
partially aggregated data was undertaken in 29 studies 
(47%). In 19 of these studies, no assessment or discussion 
of between- database heterogeneity was provided, and 
only 4 studies reported any form of analytical adjustment 
for the clustered nature of the pooled data—in each case 
by including database as a covariate in a multiple regres-
sion model, with one study also including interaction 
terms between database and covariates.27 Two- stage meta- 
analysis of database- specific effect estimates was used in 
21 studies (34%), of which 14 presented some discussion 
or formal assessment of heterogeneity. The choice of FE 
or RE models was not clearly justified in most studies, 
though in four cases model choice was based on formal 
tests of heterogeneity (results not shown).
In 41 analytical studies (66%), separate effect estimates 
were reported for each database. Between database hetero-
geneity was formally assessed (most commonly using the 
I2 statistic) in 17 studies (27%) and was discussed but not 
formally assessed in a further 6 studies (10%). In 17 studies 
(27%)—all of which used a one- stage approach—results 
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were presented for the combined dataset only. Only 2 of 
these 17 studies additionally included a two- stage meta- 
analysis and reported heterogeneity statistics.
Ten studies reported comparable results (in the main 
paper or in supplementary materials) using two or more 
analytic approaches, such as both one- stage and two- stage 
meta- analysis (nine studies), or two- stage analysis with both 
FE and RE models (one study), summarised in figure 2. 
In most cases one- stage and two- stage meta- analysis gave 
very similar results. CIs from RE meta- analysis were in 
almost every case wider than the corresponding FE or 
one- stage model estimates. In one study (review database 
id: 117), point estimates from one- stage and two- stage 
meta- analyses differed appreciably, and RE model CIs 
were wider, partly because some databases with very small 
numbers of cases were excluded.28 In one self- controlled 
case series study examining risk of upper gastrointestinal 
bleeding with different drugs alone and in combination, 
the point estimates from one- stage model (ignoring 
clustering) and two- stage RE effects models were very 
different (review database id: 113a- d), and CIs from the 
two- stage models were much wider.29
DISCUSSION
This systematic review identified 109 multi- database 
studies, which used data from 2 or more primary care 
EHR data sources, the great majority of which were 
from European countries. Just under half were descrip-
tive studies undertaken either to compare patterns and 
trends in different populations or settings, or to assess 
comparability of different EHR databases from similar 
populations. In these descriptive studies, and in a third of 
analytical studies, there was no attempt to combine results 
from the different databases. Where data was combined, 
a one- stage meta- analysis of pooled IPD was used more 
often than two- stage meta- analysis of database- specific 
results. Reporting of statistical methods for one- stage 
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Hand searches of references 
from full text articles 
(n=5) 
Figure 1 Selection and inclusion of studies for systematic review (adapted from Moher et al70).
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Table 1 General characteristics of included studies, including objective, rationale and study design
Study type
Analytical Descriptive Other* All %
All Studies 62 45 2 109
Study objective
  Drug safety 37 5 42 38.5
  Drug utilisation 3 24 1 28 25.7
  Disease epidemiology 7 9 16 14.7
  Disease risk prediction 5 2 7 6.4
  Drug comparative effectiveness 6 6 5.5
  Methodology/data quality 2 3 1 6 5.5
  Health services research 2 2 4 3.7
Main rationale for using multiple data sources (stated or inferred)
  Describe trends and variation between countries or settings 2 28 30 27.5
  Increase study power 24 2 26 23.9
  Examine consistency of findings in different settings (using a 
standardised approach or common study protocol)
19 3 22 20.2
  Compare availability/quality of data in each source 2 7 2 11 10.1
  Validation of findings in a second data source 5 3 8 7.3
  Not clearly stated 10 2 12 11.0
  Databases per study: primary care EHR only
  Mean 2.4 2.9 2.5 2.6
  Median (range) 2 (2–4) 3 (2–5) 2.5 (2–3) 2 (2–5)
Databases per study: all types
  Mean 3.1 4.3 5.0 3.7
  Median (range) 2 (2–8) 4 (2–8) 5 (2–8) 3 (2–8)
Database setting
  Single country 25 9 1 35 31.8
  Multi- country 37 36 1 75 68.2
Study design†
  Cohort study 33 38 1 72 66.1
  Case–control study 23 0 0 23 21.1
  Cross- sectional 1 6 1 8 7.3
  Self- controlled designs 7 0 0 7 6.4
  Other 0 1 1 2 1.8
  Interrupted time series 1 0 0 1 0.9
Data management and analysis model (stated or inferred)
  Centralised management and analysis: raw data shared 32 11 1 44 40.4
  Distributed management and analysis: aggregated results shared 11 12 23 21.1
  Distributed management+centralised analysis: patient level or 
partially aggregated data shared
11 8 1 20 18.3
  Not described 8 14 22 20.2
Study drug (ATC chapter)
  Nervous system 11 8 19 17.4
  Respiratory system 9 5 14 12.8
  Musculoskeletal system 9 3 12 11.0
  Multiple categories 7 4 11 10.1
Continued
6 Dedman D, et al. BMJ Open 2020;10:e037405. doi:10.1136/bmjopen-2020-037405
Open access 
studies, adjustment for clustering or effect heterogeneity 
was either not explored or not reported.
Whether and how to combine data is a key consider-
ation in multi- database studies, and our results are consis-
tent with a previous systematic review which found that 16 
out of 22 multi- database pharmacoepidemiology studies 
used a one- stage approach to combine the data.4
One- stage meta- analysis approaches have gained 
popularity over the past two decades as a technique for 
combining individual participant’ data from randomised 
controlled trials and other clinical studies that collect 
primary data, identified in systematic reviews.30–32 One- 
stage meta- analysis has a number of advantages rele-
vant to multi- database studies, which combine IPD from 
secondary data sources.33 First, it ensures standardisation 
of the statistical analysis across all data sources. Second, it 
provides maximum flexibility to explore dose–response 
patterns, subgroup analyses and effect modification, all 
of which may help to account for heterogeneity between 
data sources. Third, a one- stage approach can incor-
porate information from smaller databases with sparse 
data, even where the database- specific effect cannot be 
reliably estimated due to zero cell counts.28 34 35 However, 
one- stage meta- analysis of IPD should properly account 
for the clustered nature of the data from contributing 
databases,27 36–39 since not doing so may introduce bias, 
especially if there is between- study heterogeneity in effect 
estimates. The results of this review suggest that clustering 
Study type
Analytical Descriptive Other* All %
  Alimentary tract and metabolism 6 3 1 10 9.2
  Antiinfectives for systemic use 4 4 8 7.3
  Cardiovascular system 2 2 4 3.7
  Genito urinary system and sex hormonesc 2 1 3 2.8
  Blood and blood forming organs 2 2 1.8
  Dermatologicals 1 1 0.9
  N/A 12 12 1 25 22.9
Study condition (ICD-10 chapter)
  Diseases of the circulatory system (I00–I99) 15 4 19 17.4
  Diseases of the respiratory system (J00–J99) 11 4 15 13.8
  Diseases of the digestive system (K00–K95) 9 4 13 11.9
  Multiple categories 3 7 10 9.2
  Endocrine, nutritional and metabolic diseases (E00–E89) 4 3 2 9 8.3
  Injury, poisoning and certain other consequences of external 
causes (S00–T88)
6 1 7 6.4
  Neoplasms (C00–D49) 5 1 6 5.5
  Diseases of the musculoskeletal system and connective tissue 
(M00–M99)
4 1 5 4.6
  Diseases of the nervous system (G00–G99) 2 3 5 4.6
  Pregnancy, childbirth and the puerperium (O00–O9A) 1 3 4 3.7
  Certain infectious and parasitic diseases (A00–B99) 2 2 1.8
  Diseases of the skin and subcutaneous tissue (L00–L99) 2 2 1.8
  Diseases of the blood and blood- forming organs and certain 
disorders involving the immune mechanism (D50–D89)
1 1 0.9
  Diseases of the genitourinary system (N00–N99) 1 1 0.9
  Health status, including morbidity and/or mortality 1 1 0.9
  Mental, behavioural and neurodevelopmental disorders (F01–F99) 1 1 0.9
  N/A 8 8 7.3
*Other study type category included: case definition validation by chart review (one study) and prescribing data quality assessment (one 
study).
†Six studies included multiple designs and, therefore, included each relevant category: case–control and cohort [three studies]; 
case‐crossover and self‐controlled case series (SCCS) (two studies) and cohort study and SCCS (one study).
ATC, Anatomical Therapeutic Chemical Classification; EHR, electronic health record; ICD-10, International Classification of Diseases 10th 
Revision.
Table 1 Continued
7Dedman D, et al. BMJ Open 2020;10:e037405. doi:10.1136/bmjopen-2020-037405
Open access
is largely ignored in multi- database studies using primary 
care EHR data, and this is consistent with findings from 
other reviews of one- stage meta- analysis in systematic 
reviews,30 31 and in multi- database pharmacoepidemi-
ology studies.4 27 Barriers to the adoption of methods that 
properly account for clustering may include the perceived 
statistical complexity, lack of options in commonly avail-
able statistical software or because they can be computa-
tionally intensive.27 40
A third of analytical studies in this review used a two- stage 
approach to combine database- specific effect estimates 
to produce a pooled estimate. This approach avoids the 
need to share potentially sensitive IPD and may, therefore, 
be the only available option in some instances. It can also 
take advantage of local expertise and knowledge of each 
database partner, including optimising the use of available 
covariate information to control for confounding. In addi-
tion, a two- stage meta- analysis is relatively straightforward 








studies Other† All %
All studies 23 34 7 2 62
Statistical methods‡
  Logistic regression 23 8 2 1 34 54.8
  Poisson regression 6 6 12 19.4
  Cox regression 18 18 29.0
  Other§ 9 1 1 11 17.7
Confounder control‡
  Multiple regression or Mantel Haenszel test 23 32 2 55 88.7
  Matching 23 9 1 29 46.8
  Case only/self- controlled design 7 7 11.3
  Propensity scores 3 3 4.8
  Instrumental variables 2 2 3.2
  None 1 1 1.6
Database comparisons/heterogeneity assessment‡
  Participant characteristics presented for each 
database
17 24 4 2 45 72.6
  Effect estimates presented for each database 18 19 5 2 41 66.1
  Formal test of effect heterogeneity 10 4 3 17 27.4
  I2 6 3 3 12 19.4
  Cochran’s Q 2 1 3 4.8
  Other or not specified 3 3 4.8
  No database comparisons (combined effect 
estimates only)
5 11 2 17 27.4
Method for combining data or results‡
  Data not combined 3 16 3 2 22 35.5
  Meta- analysis (two- stage) 15 4 3 21 33.9
  Random effects 10 2 2 13 21.0
  Fixed effects 7 3 2 13 21.0
  Method not specified 1 1 1.6
  Pooled analysis (one- stage) 12 15 3 29 46.8
  Multiple: one- stage and two- stage 7 1 2 10 16.1
*Six studies contributed to multiple categories because they included multiple designs: case–control and cohort (three studies); 
case‐crossover and self‐controlled case series (SCCS) (two studies) and cohort study and SCCS (one study).
†(One cross- sectional and one interrupted time series.
‡A single study could be included in more than one category.
§Other statistical methods included: negative binomial regression (two studies); Mantel- Haenszel test (two studies); two- stage instrumental 
variable (IV) models (two studies); 'data- mining methods' (two studies); generalised linear models (one study) and univariate tests (one study).
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to implement and interpret. It is also possible to conduct 
pre- planned subgroup analyses, or examine dose–response 
effects using a two- stage approach, although sparse data 
may limit this, since databases with zero cell counts in one 
or both comparison groups will usually have to be excluded, 
unless some form of continuity correction is used, which 
can introduce bias.41
As for meta- analysis of randomised and prospective 
studies, a second key consideration for multi- database 
studies is how to assess and interpret results in the 
presence of heterogeneity. Limitations associated with 
using secondary data not collected for the specific 
study question impose an additional challenge in this 
context.1 2 Several approaches for harmonising analyses 
of multi- database studies have been used. These include 
development and adoption of consistent and validated 
case definitions, use of common protocols and statistical 
analysis plans, and shared data management and anal-
ysis routines, all aiming to reduce external sources of 
variability in results from different databases.10 11 16 17 19 
Nevertheless, in studies incorporating data from different 
countries with different population characteristics and 
healthcare systems, these factors may contribute to real 
differences in the effect estimates. Even within a single 
country, different primary care EHR software systems are 
used, which may introduce heterogeneity in the extracted 
data.42–47 With one- stage analysis, both clustering and 
heterogeneity can be naturally explored in hierarchical 
models incorporating FE and/or RE, though as already 
noted the tendency has been to ignore this issue in multi- 
database studies. For two- stage meta- analysis, we found 
that FE and RE models were used equally frequently and 
model choice, where discussed at all, was generally related 
to the presence or absence of heterogeneity. Relatively 
few studies justified the choice based on some formal 
measure or test for heterogeneity, a practice which has 
been criticised because such tests often have low power. 
This is a problem especially when the number of studies 
or databases is small,48 and can result in an FE model 
being used even though heterogeneity is present and an 
RE model may have been more appropriate.49 Simulation 
studies have shown that the I2 statistic can also be unre-
liable, either underestimating or overestimating hetero-
geneity in certain circumstances, particularly when the 
number of studies or databases is small.50 51
Several countries (Italy, Netherlands, Spain and the UK) 
now have two or more primary care EHR databases, and 
combining sources from the same country may reduce 
heterogeneity. In such cases, an FE model may be appro-
priate, especially where supporting analyses demonstrate 
substantial similarities in patient characteristics. Of eight 
single- country studies identified in this review and using 
two- stage meta- analysis, all eight used FE models52–59—
despite evidence of substantial heterogeneity in some 
cases, although two studies did also use RE models for 
some analyses.52 53
When combining primary care EHR data from 
different countries or settings, an RE model might seem 
most appropriate, since these incorporate uncertainty in 
effect size when heterogeneity is present, yet reduce to an 
FE model if there is no heterogeneity.48 However, when 
the number of estimates being combined is very small 
(<5) and heterogeneity is present—a common scenario 
in multi- database studies—conventional RE models may 
Figure 2 Comparison of relative risk (RR) estimates reported in studies using two or more methods to combine data from 
multiple sources. [study] refers to the review database id number (see online supplemental table S1).
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perform poorly. Simulation studies show that they can 
produce CIs which are too narrow, thereby increasing type 
one error rates.60–63 A number of alternatives to conven-
tional RE models have been proposed which partially 
address these limitations in some circumstances60 63–66; 
nevertheless, several authors have urged caution when 
interpreting results from meta- analysis of very few hetero-
geneous studies.60 63 66 For multi- database studies, it may, 
therefore, be helpful to present estimates for both FE and 
RE models—or other alternative models, but always along 
with the results from individual databases.
Despite the differences outlined above, where studies 
combined data using more than one method, they 
produced similar estimates in most cases. However, in at 
least one study, one- stage and two- stage methods yielded 
large differences in both the point estimates and their 
precision. This may in part be related to the substantial 
heterogeneity in the database- specific estimates (reported 
I2 between 86% and 98% for the estimates shown), but 
incomplete reporting of statistical methods limits further 
interpretation of these results. When the same modelling 
assumptions are used, one- stage and two- stage approaches 
are expected to give very similar results if the number of 
studies combined is relatively large.37 However, few studies 
have systematically compared performance of one- stage 
and two- stage approaches for multi- database studies.27 67
Limitations
The search strategy for this review included a list of named 
primary care EHR databases compiled from publicly avail-
able registers. This was to circumvent the poor sensitivity 
and specificity of conceptual searches based on MeSH 
terms, as reported in a previous review,4 and confirmed 
in the current review. Our approach could have missed 
some eligible studies—if the abstract only mentioned 
primary care EHR data sources that were not in our list 
or did not mention the use of health databases or related 
terms at all. We would also have missed non- English 
language and abstract- only publications. Nevertheless, we 
expect the number of missed studies to be small, and any 
such studies are unlikely to have differed systematically 
from the included studies in terms of key methodolog-
ical aspects. A more recent inventory of EHR databases 
in Europe did not identify any additional primary care 
databases that were not included in our review.68 A 
further limitation was that some subjective interpretation 
was occasionally necessary to classify aspects of certain 
studies—for example, the rationale for combining, or the 
methods for managing and analysing data. The use of two 
reviewers helped to achieve some consistency across the 
included studies.
In conclusion, we found a growing body of literature 
reporting on studies using two or more sources of primary 
care EHR data. These addressed a range of research 
questions, and in many cases the results were presented 
separately and not combined. When data was combined, 
a one- stage meta- analysis was preferred. One- stage 
methods offer advantages in terms of analytical flexibility 
but are only possible where data management and gover-
nance arrangements allow for sharing of IPD. However, 
in many studies using one- stage approaches, the clustered 
nature of data from multi- database studies was frequently 
ignored, with unknown impact for interpretation. Two- 
stage meta- analysis requires only sharing of aggregated 
results, but there are known limitations with current 
two- stage methods when the number of studies is small, 
especially when some heterogeneity is expected. Irrespec-
tive of whether a one- stage or two- stage approach is used, 
combined results should be accompanied by results from 
each data source separately. This information, together 
with clear and complete reporting on methods used to 
Table 3 Recommendations
Recommendation Rationale
Studies should report clearly on all aspects of study design 
and conduct which impact on harmonisation of analyses 
across data sources.
Allows assessment of the relative importance of heterogeneity 
induced by data management and analysis decisions vs 
heterogeneity inherent in the data.
Participant characteristics and effect estimates (where 
applicable) should be reported for each data source.
Assessment of heterogeneity is essential for interpretation, but 
formal methods for quantifying heterogeneity are inefficient and 
possibly biased in multi- database settings.
Where one- stage methods are used, studies should report 
whether and how analyses accounted for clustering and 
between database heterogeneity.
Interpretation requires understanding of extent to which 
heterogeneity might influence study results.
Where two- stage meta- analysis is used, studies should 
provide a clear rationale for choice of fixed effect (FE), 
random effects (RE) or other model.
Interpretation requires understanding of extent to which 
heterogeneity might influence study results.
Sensitivity analyses should include alternative methods for 
combining data.
Comparing the results of one- stage vs two- stage analyses, or 
FE vs RE models, provides information about potential impact 
of modelling assumptions.
Further research is needed to compare performance of one- 
stage and two- stage approaches for multi- database studies.
Relatively few studies have specifically addressed meta- 
analysis for multi- database studies.
10 Dedman D, et al. BMJ Open 2020;10:e037405. doi:10.1136/bmjopen-2020-037405
Open access 
standardise and analyse the data (including the rationale 
for these decisions), affords a more considered assess-
ment of potential sources of heterogeneity and greatly 
aids interpretation of the overall results. These consider-
ations are relevant more widely to multi- database studies 
irrespective of the types of EHR or administrative data-
bases being used, particularly where the number of data-
bases being combined is relatively small, as was generally 
the case in our sample. Further research is required to 
understand the impact of analysis methods and other 
design aspects on overall study quality, and the develop-
ment of reporting guidelines for multi- database studies, 
or extension of the existing RECORD guidance,69 might 
be an important first step. Table 3 summarises key recom-
mendations arising from our review.
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